Immuno-oncology therapies: a looming mid-life crisis?
Loading...
File version
Version of Record (VoR)
Author(s)
Kim, Hansoo
Liew, Danny
Goodall, Stephen
Liew, Danny
Goodall, Stephen
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
Abstract
The introduction of immune-oncology therapies for the treatment of cancer marked a shift away from targeting cells to utilising the immune system to fight cancer. These therapies have become standard of care for many different tumour types [1] as they offer the possibility of long-term survival and improved toxicity profile for cancer patients when compared to chemotherapies.
Journal Title
Immuno-Oncology Insights
Conference Title
Book Title
Edition
Volume
3
Issue
2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2022 Kim H, Liew D, Goodall S. Published by Immuno-Oncology Insights under Creative Commons License Deed CC BY NC ND 4.0.
Item Access Status
Note
Access the data
Related item(s)
Subject
Persistent link to this record
Citation
Kim, H; Liew, D; Goodall, S, Immuno-oncology therapies: a looming mid-life crisis?, Immuno-Oncology Insights, 2022, 3 (2), pp. 73-79